China has issued the first patent for the COVID-19 vaccine, although it has not yet been tested in humans
During research, the drug showed good results when tested on mice and guinea pigs.
The State Intellectual Property Office of China has issued the first patent for the vaccine from COVID-19. It was received by the Academy of Military Medical Sciences of the People’s Liberation Army and CanSino Biologics, Xinhua reports .
The Ad5-nCoV vaccine was developed by a team of scientists led by Chen Wei, a researcher at the Institute of Military Medicine at the academy.
The vaccine is based on viral vector technology. Once in the body, the vaccine causes a reaction that resembles COVID-19 irritation. The immune system “considers” that it has encountered SARS-CoV-2 and produces the appropriate antibodies. The Ad5-nCov vaccine should be given once.
The vaccine was admitted to clinical trials in March. However, it has not yet been tested on humans. Studies in mice and guinea pigs have shown good results. The developers of the vaccine will assure that it can be easily made. This will ensure its rapid mass production.
It will be recalled that immunity to HCoV coronaviruses, which is present in most people, does not provide cross-protection against the SARS-CoV-2 pathogen. This is evidenced by a study by French doctors. To do this, scientists analyzed blood samples from 76 healthy French people. They were all immune to HCoV. In only six cases did the immune system successfully resist the SARS-CoV-2 virus.